## Aiforia Technologies Plc's financial reporting and Annual General Meeting in financial year 2024

Aiforia Technologies Plc, Company release, December 4, 2023 at 09:00 a.m. EET

The calendar for Aiforia Technologies Plc's financial reporting concerning the financial year 2024 is as follows:

- March 7, 2024: Financial Statements Bulletin for financial year 2023
- March 13, 2024: The Financial Statements and the Board of Directors' Report for financial year 2023
- August 29, 2024: Half-Year Financial Report for 1 January–30 June 2024

Aiforia Technologies's Annual General Meeting will be held on April 4, 2024. The Board of Directors will convene the meeting with a separate company release at a later date.

More information on the events of the financial year will be available on the company's investor pages at <a href="https://investors.aiforia.com/investor-calendar">https://investors.aiforia.com/investor-calendar</a>.

## **Further inquiries**

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878 <a href="https://investors.aiforia.com/">https://investors.aiforia.com/</a>

## **Certified Adviser**

UB Securities Ltd <a href="mailto:ubs@unitedbankers.fi">ubs@unitedbankers.fi</a>

## **About Aiforia**

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, Al and software developers, and a dedicated commercial team. Together, they are working to transform pathology with Al, enabling better care for each patient.

Find out more at <u>www.aiforia.com</u>